Roivant Shares Jump After Strong Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis
Roivant Sciences reported robust Phase 2 findings for brepocitinib in cutaneous sarcoidosis, prompting a 15% rise in its stock. The 45 mg dose produced a 22.3-point mean improvement on CSAMI-A at Week 16 versus 0.7 points for placebo, a statistically significant difference of 21.6 points. The company plans a Phase 3 program in 2026 and reported $4.…